Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells

Urologia Internationalis

Volumn 88, Issue 1, 2012, Pages 95-101

  Li, Yangle ^a   Zhao, Xiaokun ^a   Tang, Huiting ^b   Zhong, Zhaohui ^a   Zhang, Lei ^a   Xu, Ran ^a   Li, Songchao ^a   Wang, Yi ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Bladder transitional carcinoma cell; Hypoxia inducible factor 1 ; Migration; Proliferation; T24; YC 1

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIFICIGUAT; MESSENGER RNA; PROTEIN BCL 2; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; BLADDER TRANSITIONAL CARCINOMA; CANCER CELL CULTURE; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; INCUBATION TIME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; TRANSITIONAL CELL CARCINOMA; TUMOR GENE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INDAZOLES; MATRIX METALLOPROTEINASE 2; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; UP-REGULATION; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84856464837     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000331881     Document Type: Article

References (28)

1. Lerner SP: Bladder cancer clinical trials. Urol Oncol 2005;23:275-279.
2. von der Maase H, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-3077.
3. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
4. Brown JM, Giaccia AJ: The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998;58:1408-1416.
5. Benizri E, Ginouves A, Berra E: The magic of the hypoxia-signaling cascade. Cell Mol Life Sci 2008;65:1133-1149.
6. Chan DA, Krieg AJ, Turcotte S, et al: HIF gene expression in cancer therapy. Methods Enzymol 2007;435:323-345.
7. Semenza GL: Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 2008;60:591-597.
8. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5835.
9. Birner P, Schindl M, Obermair A, et al: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-4696.
10. Theodoropoulos VE, Lazaris A, Sofras F, et al: Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004;46:200-208.
11. Deniz H, Karakok M, Yagci F, et al: Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas. Int Urol Nephrol 2010;42:103-107.
12. Ko FN, Wu CC, Kuo SC, et al: YC-1, a novel activator of platelet guanylate cyclase. Blood 1994;84:4226-4233.
13. Yeo EJ, Chun YS, Park JW: New anticancer strategies targeting HIF-1. Biochem Pharmacol 2004;68:1061-1069.
14. Chun YS, Yeo EJ, Choi E, et al: Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001;61:947-954.
15. Kim HL, Yeo EJ, Chun YS, et al: A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. Int J Oncol 2006;29:255-260.
16. Giaccia A, Siim BG, Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Discov 2003;2:803-811.
17. Chiang WC, Teng CM, Lin SL, et al: YC-1-inhibited proliferation of rat mesangial cells through suppression of cyclin D1-independent of cGMP pathway and partially reversed by p38 MAPK inhibitor. Eur J Pharmacol 2005;517:1-10.
18. Lau CK, Yang ZF, Lam CT, et al: Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochem Biophys Res Commun 2006;348:1443-1448.
19. Li SH, Shin DH, Chun YS, et al: A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}. Mol Cancer Ther 2008;7:3729-3738.
20. Maxwell PH, Dachs GU, Gleadle JM, et al: Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104-8109.
21. Chai CY, Chen WT, Hung WC, et al: Hypoxiainducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol 2008;61:658-664.
22. Yeo EJ, Chun YS, Cho YS, et al: YC-1: a potential anticancer drug targeting hypoxiainducible factor 1. J Natl Cancer Inst 2003;95:516-525.
23. Zhao Q, Du J, Gu H, et al: Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas 2007;34:242-247.
24. Feng Y, Zhu H, Ling T, et al: Effects of YC-1 targeting hypoxia-inducible factor 1 alpha in esophageal squamous carcinoma cell line Eca109 cells. Cell Biol Int 2011;35:491-497.
25. Semenza GL, Agani F, Booth G, et al: Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997;51:553-555.
26. Chen CJ, Hsu MH, Huang LJ, et al: Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochem Pharmacol 2008;75:360-368.
27. Liu C, Shi Y, Du Y, et al: Dual-specificity phosphatase DUSP1 protects overactivation of hypoxia-inducible factor 1 through inactivating ERK MAPK. Exp Cell Res 2005;309:410-418.
28. Ryan S, McNicholas WT, Taylor CT: A critical role for p38 MAP kinase in NF-kappaB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 2007;355:728-733.